APA

Fizazi K., Scher H. I., Molina A., Logothetis C. J., Chi K. N., Jones R. J., Staffurth J. N., North S., Vogelzang N. J., Saad F., Mainwaring P., Harland S., Goodman O. B., Sternberg C. N., Li J. H., Kheoh T., Haqq C. M. & de Bono J. S. (20121207). Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. : The Lancet. Oncology.

Chicago

Fizazi Karim, Scher Howard I, Molina Arturo, Logothetis Christopher J, Chi Kim N, Jones Robert J, Staffurth John N, North Scott, Vogelzang Nicholas J, Saad Fred, Mainwaring Paul, Harland Stephen, Goodman Oscar B, Sternberg Cora N, Li Jin Hui, Kheoh Thian, Haqq Christopher M and de Bono Johann S. 20121207. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. : The Lancet. Oncology.

Harvard

Fizazi K., Scher H. I., Molina A., Logothetis C. J., Chi K. N., Jones R. J., Staffurth J. N., North S., Vogelzang N. J., Saad F., Mainwaring P., Harland S., Goodman O. B., Sternberg C. N., Li J. H., Kheoh T., Haqq C. M. and de Bono J. S. (20121207). Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. : The Lancet. Oncology.

MLA

Fizazi Karim, Scher Howard I, Molina Arturo, Logothetis Christopher J, Chi Kim N, Jones Robert J, Staffurth John N, North Scott, Vogelzang Nicholas J, Saad Fred, Mainwaring Paul, Harland Stephen, Goodman Oscar B, Sternberg Cora N, Li Jin Hui, Kheoh Thian, Haqq Christopher M and de Bono Johann S. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. : The Lancet. Oncology. 20121207.